![]() |
|
|
|
Prof. Richard F. Lockey, MD, and WAO Web Editor-in-Chief, reviewed premier January medical journal articles for practicing allergists. Read his top 3 picks below and for the other 9 reviews, click here.
1. Rapid Effects of Inhaled Corticosteroids in Acute Asthma Seventeen studies (470 adults and 663 children and adolescents) met the criteria for inclusion in this review of treatment with inhaled corticosteroids (ICS) within one to four hours of presentation of an asthma exacerbation. Final outcomes were admission and ED discharge rates. After the 2- to 4- hour protocol, a greater reduction of admission rate was observed in trials that used multiple doses of ICS, especially when compared with placebo (odds ratio{OR}, 0.30; 95% confidence interval {CI}, 0.16 to 0.55). ICS patients improve more rapidly when compared with placebo or systemic corticosteroids (SCS) increasing the probability of early ED discharge (OR 4.70; 95% CI, 2.97 to 7.42; p = 0.0001). Spirometric and clinical measures improved as early as 60 minutes with ICS. Benefits were obtained only when patients received multiple doses of ICS with ß-agonist compared with placebo or SCS. In conclusion, ICS used early in multiple doses administered in time intervals of < or = to 30 minutes over 90 to 120 minutes are especially beneficial. Editor's comment: High dose ICS plus ß-agonists used within four hours on multiple occasions for acute asthma effectively decreases morbidity from severe asthma exacerbations. Rodrigo GJ, Chest 2006; 130: 1301 2. Effects of Continuing or Stopping Alendronate (A) After 5 Years of Treatment One thousand and ninety-nine (1099) postmenopausal women with a mean of five years of prior A treatment were randomized to A, 5 mg/d (n = 329) or 10 mg/d (n = 333), or placebo (P) (n = 437) for five years. Compared with A, switching to P resulted in declines in bone mineral density (BMD) at the total hip (P< .001) and spine (P<.001), but mean levels remained at or were above pretreatment levels 10 years earlier. The cumulative risk for nonvertebral fractures was not significantly different between the two groups. Those on A had significantly lower risks of clinically recognized vertebral fractures (5.3% for P, 2.4% for A) but no significant reduction in morphometric vertebral fractures (11.3% for P, 9.8% for A). The authors suggest that the discontinuation of A after five years does not significantly increase the fracture risk, however, women at high risk of clinical vertebral fractures may benefit by continuation of A. Editor's comment: Physicians who treat asthma and allergic and immunologic diseases need to know how to diagnosis and treat osteopenia and osteoporosis. SG. Black DM, et al. JAMA 2006; 296: 2927. Editorial, Colón-Emeric C. JAMA 2006; 296: 2968. 3. Long-Term Proton Pump Inhibitor (PPI) Therapy and Risk of Hip Fracture This is a nested, case-control study using a research database from the United Kingdom. The cohort consisted of users of PPI therapy versus nonusers of acid suppression drugs older than 50 years. Similar nested, case-control analysis for histamine 2 receptor antagonists was performed. The adjusted odds ratio (AOR) for hip fractures associated with more than one year of PPI therapy was 1.44 (95% confidence interval [CI], 1.30-1.59). For long-term high dose PPIs (AOR, 2.65; 95% CI, 1.80-3.90; P<.001). The risk increased with duration of PPI therapy, i.e., up to four years. The authors conclude that PPI therapy significantly increases the risk of hip fracture, possibly secondary to acid suppression and decreased calcium absorption. Editor's comment: The risk-benefit of PPI therapy needs to be considered. Individuals with asthma commonly have gastroesophageal reflux disease. Using the lowest effective PPI dose and increasing consumption of dairy products, calcium supplements with meals, and vitamin D therapy make sense. Yang Y-X, et al. JAMA 2006; 296: 2947. To read the additional reviews, click here.
World Allergy Forum"A Global Perspective on Genetics, the Environment and Allergy" 2007 AAAAI Annual Meeting Monday, February 26, 2007, 4:45 pm - 6:00 pm San Diego Convention Center Upper Level, Room 32 AB Moderator: Thomas A. E. Platts-Mills, USA Co-Moderator: Michael A. Kaliner, USA Is Early Exposure to Allergen Protective? Adnan Custovic, United Kingdom How Does the Environment Influence Genetic Responses? Robert F. Lemanske Jr., USA Environmental Intervention in the Management of Allergic Diseases Erika Von Mutius, Germany
2007 March GLORIA PlacementsScientific Meeting of the Association of Allergology and Clinical Immunology of Serbia and Montenegro 22-24 March 2007 Belgrade, Serbia International GLORIA Faculty: Todor Popov Presentations: Module 7: Angioedema Module 9: Diagnosis of IgE Sensitization South Carolina Society of Allergy, Asthma, and Immunology March 23-25, 2007 Charleston, South Carolina US GLORIA Faculty: Allen P. Kaplan Presentations: Module 2: Allergic Conjunctivitis Module 8: Anaphylaxis The WAO Henning Løwenstein Research Award 2007 Call for Applications The WAO Henning Løwenstein Research Award is a biennial award given to a young scientist who has shown excellence within the field of allergy. WAO and ALK-Abelló will present the award at the World Allergy Congress in Bangkok, 2-6 December 2007. The winner will receive EURO 20,000 together with a travel grant to attend the Congress. Deadline: 30 June 2007 New Synopsis Drug Allergies are the focus of the latest educational synopsis to be posted on the WAO Web site. Written by Bernard Thong, MBBS, MRCP (UK), FAAAAI, with contributions from Cassim Motala, MD FCPAED(SA) FACAAI FAAAAI , and Daniel Vervloet, MD FAAAAI, the synopsis provides a comprehensive overview of immunological and non-immunological adverse drug reactions. To read this new synopsis in WAO's Allergic Diseases Resource Center, click here. WAO Conversations: We have the pleasure of announcing four new interviews with well-respected allergists. Take a moment to listen to them sharing their extensive knowledge.
Dr. Dalia El-Ghoneimy from Cairo, Egypt, spent her WAO Short-Term Research Fellowship in the laboratory of Prof. G. Walter Canonica in Genoa, Italy, studying skin prick testing in the early diagnosis of atopy in infants and children and immunotherapeutic modalities. The objective of her fellowship was to receive the necessary training to enable her to identify the major allergens to which infants in Egypt are sensitized and the possible immunotherapeutic interventions needed. To read Dr. El-Ghoneimy's report on her fellowship, click here. Sign up for On-Line Journal Subscription - WAO and Hogrefe & Huber Publishers are offering a limited number of free on-line subscriptions to Allergy & Clinical Immunology International - Journal of the World Allergy Organization for members in developing countries. If you are interested in receiving a complimentary, on-line subscription, please send an e-mail to info@worldallergy.org, noting "Free Journal Subscription" in the subject line, with the following details: First name Last name Postal address City, State/Province and postal code Country E-mail address Name of Member Society
Find more allergy book reviews on the WAO Website here. |
|
|
WAO's mission is to be a global resource and advocate in the field of allergy, advancing excellence in clinical care through education, research and training as a world-wide alliance of allergy and clinical immunology societies. Visit us on the Web at www.worldallergy.org World Allergy Organization (WAO) Secretariat 555 E. Wells Street, Suite 1100 Milwaukee, WI 53202-3823 Email: info@worldallergy.org You have received this message because you are a member of a WAO Member Society, you have subscribed for the monthly e-letter or had previous contact with the World Allergy Organization. If you would prefer not to receive further messages from WAO, please reply to this message with REMOVE in the subject line. Made possible through an unrestricted educational grant from Novartis. |
|